A new study that will be published this month has found a drug that was originally developed to treat kidney cancer may also prove effective in limiting the spread of mesothelioma in patients as well.
The research, which was conducted by the Institute of Cancer Research at the Medical University of Vienna and published in the May issue of the Journal of Thoracic Oncology, found that temsirolimus – the kinase inhibitor – was able to slow the growth of malignant pleural mesothelioma cells in patients.
The drug’s ability to do this was linked to it being able to block mTOR-mediated signals, which in turn stopped the growth of the cells. The drug was originally designed to slow tumor growth and treat kidney cancer and renal cell carcinoma.
Even more interesting was the study’s revelation that the drug was able to limit the growth of cells that had been resistant to treatment by cisplastin – a drug commonly used in mesothelioma chemotherapy treatments.
“In our preclinical study, published in the [Journal], we were able to demonstrate that inhibition of the major oncogene mTOR is active against human mesothelioma especially after development of chemotherapy resistance both in vitro and in vivo,” said Dr. Walter Berger, a professor at the Institute of Cancer Research at the Medical University of Vienna. “These results suggest the initiation of clinical trials involving mTOR inhibitors as a novel anti-mesothelioma strategy.”
Living with the day-to-day hardships of mesothelioma – whether it is you or a loved one who has been diagnosed with the illness – is both emotionally and financially taxing for all who are involved. If you feel that a company or former employer may be responsible for the asbestos exposure that led to an illness, contact a mesothelioma attorney to learn about filing a mesothelioma lawsuit.